Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 10:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: PVR Clear all
Not listed Phase 2 Interventional Accepts healthy volunteers

Intravitreal Aflibercept for the Prevention of Proliferative Vitreoretinopathy Following Retinal Detachment Repair

NCT04580147
View directory record Official record
Conditions
Retinal Detachment With Multiple Breaks, Unspecified Eye, Proliferative Vitreoretinopathy
Interventions
Intravitreal aflibercept injection, Sham control
Drug · Other
Lead sponsor
M. Ali Khan, MD
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 2, 2022 · Synced Sep 6, 2026, 10:54 AM EDT
Completed Early Phase 1 Interventional

Adrenocorticotropic Hormone (ACTH) for Post-op Inflammation in Proliferative Vitreoretinopathy (PVR)

NCT03727776
View directory record Official record
Conditions
Proliferative Vitreoretinopathy
Interventions
Adrenocorticotropic Hormone
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 7, 2023 · Synced Sep 6, 2026, 10:54 AM EDT
Terminated No phase listed Observational

Pro-permeability and Pro-fibrosis Factors in the Aqueous of Patients With Retinal Diseases

NCT02688309
View directory record Official record
Conditions
Macular Edema, Fibrosis of the Retina
Interventions
Ozurdex, Surgery, Anterior Chamber (AC) Tap
Drug · Procedure
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 7, 2022 · Synced Sep 6, 2026, 10:54 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Unmasking Right Ventricular and Pulmonary Derangements With Exercise and Oxygen in Early Stage Cardiopulmonary Diseases

NCT03911856
View directory record Official record
Conditions
Cardiopulmonary Disease
Interventions
Echocardiography, Pulmonary Gas Exchange
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 11, 2024 · Synced Sep 6, 2026, 10:54 AM EDT
Completed Phase 3 Interventional Results available

The GUARD Trial - Part 1: A Phase 3 Clinical Trial for Prevention of Proliferative Vitreoretinopathy

NCT04136366
View directory record Official record
Conditions
Proliferative Vitreoretinopathy
Interventions
ADX-2191 (intravitreal methotrexate 0.8%), Standard surgical care procedure
Drug · Other
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
23
States / cities
Phoenix, Arizona • Los Angeles, California • Orlando, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2025 · Synced Sep 6, 2026, 10:54 AM EDT
Completed No phase listed Observational

Brain Imaging in Men With Lower Urinary Tract Symptoms

NCT03991429
View directory record Official record
Conditions
Voiding Disorders
Interventions
Simultaneous functional MRI and urodynamic studies, Questionnaires, Post Void Residual (PVR), Uroflow and Bladder Diary, Urinalysis
Diagnostic Test · Behavioral · Other
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
45 Years to 90 Years · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 4, 2023 · Synced Sep 6, 2026, 10:54 AM EDT
Terminated Phase 2 Interventional

PRIMEx - A Study of 2 Doses of Oral CXA-10 in Pulmonary Arterial Hypertension (PAH)

NCT03449524
View directory record Official record
Conditions
PAH
Interventions
75mg CXA-10, 150mg CXA-10, Placebo
Drug · Other
Lead sponsor
Complexa, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
40
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2020 · Synced Sep 6, 2026, 10:54 AM EDT
Not listed Phase 2Phase 3 Interventional

A Multi-Center Study on the Use of Rho-Kinase Inhibitor to Reduce or Prevent PVR in RRD Eyes at High Risk for PVR

NCT05660447
View directory record Official record
Conditions
Rhegmatogenous Retinal Detachment, Proliferative Vitreoretinopathy
Interventions
Netarsudil 0.02% Ophthalmic Solution [RHOPRESSA], Glycerin 0.2%/Hypromellose 0.2%/Peg 1%/Soln,Oph,Ud
Drug
Lead sponsor
Wills Eye
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 29, 2024 · Synced Sep 6, 2026, 10:54 AM EDT
Active, not recruiting Phase 1 Interventional

A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab

NCT05378425
View directory record Official record
Conditions
Cancer, Tumor, Solid, Advanced Solid Tumor, Metastatic Cancer, Locally Advanced Solid Tumor
Interventions
NTX-1088, Pembrolizumab
Drug
Lead sponsor
Nectin Therapeutics Ltd
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
3
States / cities
Duarte, California • New Orleans, Louisiana • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Sep 6, 2026, 10:54 AM EDT
Not listed No phase listed Observational

PV Loop and Pulmonary Hypertension

NCT05484596
View directory record Official record
Conditions
Pulmonary Vascular Resistance Abnormality
Interventions
Measuring VA Coupling
Procedure
Lead sponsor
Hythem Nawaytou
Other
Eligibility
1 Year to 21 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
2
States / cities
San Francisco, California • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 25, 2023 · Synced Sep 6, 2026, 10:54 AM EDT
Enrolling by invitation Phase 3 Interventional

A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension

NCT03683186
View directory record Official record
Conditions
PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease
Interventions
Ralinepag
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
48
States / cities
Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 38 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Sep 6, 2026, 10:54 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Topical Netarsudil for the Prevention of Proliferative Vitreoretinopathy in Patients With Retinal Detachment

NCT06033703
View directory record Official record
Conditions
Rhegmatogenous Retinal Detachment, Proliferative Vitreoretinopathy
Interventions
Netarsudil Ophthalmic
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Sep 6, 2026, 10:54 AM EDT
Completed Not applicable Interventional

Patient Self Measurement of Post-Void Residual Bladder Volume (PVR) Using Ultrasound

NCT05295823
View directory record Official record
Conditions
Voiding Disorders, Voiding Dysfunction
Interventions
Butterfly portable ultrasound device with bladder ultrasound images, Butterfly portable ultrasound device with abstract bladder images
Device
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 14, 2023 · Synced Sep 6, 2026, 10:54 AM EDT
Completed Phase 3 Interventional

A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

NCT03626688
View directory record Official record
Conditions
PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease
Interventions
Ralinepag, Placebo
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
687 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
68
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Sep 6, 2026, 10:54 AM EDT
Completed Phase 2 Interventional Results available

Bevacizumab Against Recurrent Retinal Detachment

NCT02192970
View directory record Official record
Conditions
Retinal Detachment, Proliferative Vitreoretinopathy
Interventions
Bevacizumab
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 25, 2021 · Synced Sep 6, 2026, 10:54 AM EDT
Not listed No phase listed Observational

Assessment of the TGF-beta Pathway and Micro-RNA in Pediatric Pulmonary Arterial Hypertension

NCT04489251
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Protein Elisa analysis, microRNA analysis, whole exome sequencing
Diagnostic Test
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
2 Years to 17 Years
Enrollment
40 participants
Timeline
2020 – 2023
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 21, 2021 · Synced Sep 6, 2026, 10:54 AM EDT
Recruiting Phase 2 Interventional

Study of TX000045 in Participants With Pulmonary Hypertension Due to Interstitial Lung Disease

NCT07473700
View directory record Official record
Conditions
Hypertension, Pulmonary, Lung Diseases, Interstitial
Interventions
TX000045
Drug
Lead sponsor
Tectonic Operating Company, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
4
States / cities
Phoenix, Arizona • San Francisco, California • Idaho Falls, Idaho + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2026 · Synced Sep 6, 2026, 10:54 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Void Trials After Two Voiding Trials (TVT)

NCT03937531
View directory record Official record
Conditions
Postoperative Voiding Dysfunction, Postoperative Urinary Retention
Interventions
Bladder Scanner
Procedure
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 27, 2020 · Synced Sep 6, 2026, 10:54 AM EDT
Completed No phase listed Observational

The Regulation of Pulmonary Vascular Resistance in Patients With Heart Failure

NCT02275793
View directory record Official record
Conditions
Diastolic Heart Failure, Pulmonary Hypertension
Interventions
Not listed
Lead sponsor
University of Toledo Health Science Campus
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 17, 2019 · Synced Sep 6, 2026, 10:54 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Sedation With Dexmedetomidine During Cardiac Catheterization

NCT01072643
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Dexmedetomidine
Drug
Lead sponsor
Aruna Nathan
Other
Eligibility
8 Years to 21 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 15, 2019 · Synced Sep 6, 2026, 10:54 AM EDT
Completed Phase 2 Interventional

Inhaled Treprostinil in Sarcoidosis Patients With Pulmonary Hypertension

NCT03814317
View directory record Official record
Conditions
Sarcoidosis, Precapillary Pulmonary Hypertension, Interstitial Lung Disease
Interventions
Inhaled Treprostinil
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 99 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Sep 6, 2026, 10:54 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Reducing Postoperative Catheterization

NCT03009968
View directory record Official record
Conditions
Urinary Retention, Urinary Incontinence, Pelvic Organ Prolapse, Urinary Tract Infections
Interventions
Post-void residual free voiding trial
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 18, 2018 · Synced Sep 6, 2026, 10:54 AM EDT
Recruiting Phase 2 Interventional

Prevention of ProliFerative Vitreoretinopathy with Intravitreal MethotreXate in Primary Retinal DEtachment Repair (FIXER) Trial

NCT06541574
View directory record Official record
Conditions
Proliferative Vitreoretinopathy, Rhegmatogenous Retinal Detachment
Interventions
Methotrexate Injection, Methotrexate Infusion, Sham Injection
Drug
Lead sponsor
Cincinnati Eye Institute, Southwest Ohio
Other
Eligibility
18 Years and older
Enrollment
860 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 6, 2026, 10:54 AM EDT
Terminated No phase listed Observational

A Multi-center, International Prospective Follow up Study

NCT04579913
View directory record Official record
Conditions
Benign Prostatic Hyperplasia (BPH)
Interventions
Review of medical history, administration of questionnaires, uroflowmetry and PVR as measured by ultrasound
Other
Lead sponsor
Medi-Tate Ltd.
Industry
Eligibility
Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
4
States / cities
Pompano Beach, Florida • Manhattan, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 28, 2021 · Synced Sep 6, 2026, 10:54 AM EDT